As oncology drug costs continue to rise and many patients experience financial distress in part owing to out-of-pocket drug costs, calls to reduce oncology drug prices are gaining public support and political traction.1,2 However, politically viable policy interventions will not be free and will entail tradeoffs that may reduce patient access to cancer medications.